Nuclera Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 127

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $75M

  • Investors
  • 22

Nuclera General Information

Description

Developer of an automated construct platform designed to power up drug discovery workflows. The company allows researchers to accelerate their protein projects by screening and synthesizing proteins on terms and bench, enabling healthcare professionals with integrated cell-free protein synthesis and digital microfluidics on smart cartridges that allow progress through automated, high-throughput protein access systems.

Contact Information

Website
www.nuclera.com
Formerly Known As
Nuclera Nucleics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • One Vision Park, Station Road, Impington
  • Impington
  • Cambridge CB24 9NP
  • England, United Kingdom
+44 01223
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Other Devices and Supplies
Vertical(s)
Life Sciences
Corporate Office
  • One Vision Park, Station Road, Impington
  • Impington
  • Cambridge CB24 9NP
  • England, United Kingdom
+44 01223

Nuclera Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nuclera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC (Series C) 06-Aug-2024 $75M Completed Generating Revenue
11. Grant 06-Jun-2024 Completed Generating Revenue
10. Accelerator/Incubator 19-Mar-2024 Completed Generating Revenue
9. Secondary Transaction - Private Completed Generating Revenue
8. Later Stage VC (Series B) 06-Jul-2022 Completed Generating Revenue
7. Later Stage VC (Series A) 01-Oct-2019 Completed Generating Revenue
6. Accelerator/Incubator 22-Feb-2017 Completed Startup
5. Grant 01-Jul-2015 Completed Startup
4. Grant 01-Jul-2014 $42.3K $837K Completed Startup
3. Grant 01-May-2014 $167K $837K Completed Startup
To view Nuclera’s complete valuation and funding history, request access »

Nuclera Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series B
Ordinary
Ordinary
Ordinary 39,499 $0.000122 $4.88 $4.88 1x $4.88 0.53%
Ordinary 250,000 $0.000122 $2.45 $2.45 1x $2.45 3.38%
To view Nuclera’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Nuclera Patents

  • 301

    Total Documents Applications and Grants

  • Total Patents Families

  • 106

    Granted

  • 101

    Pending

  • Expiring in next 12 mo

Nuclera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202505496-D0 Assays for membrane proteins Pending 11-Apr-2025
GB-202505375-D0 Assays for gpcr proteins Pending 10-Apr-2025
GB-202505044-D0 Nucleic acid expression constructs Pending 03-Apr-2025
GB-202504053-D0 Novel amino acid sequences and uses thereof Pending 20-Mar-2025
GB-202503544-D0 Assays for membrane proteins Pending 11-Mar-2025
To view Nuclera’s complete patent history, request access »

Nuclera Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nuclera Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cambridge Innovation Capital Venture Capital Minority
Elevage Medical Technologies Growth/Expansion Minority
E-Link Holdings Venture Capital Minority
Angel (individual) Minority
Patient Square Capital PE/Buyout Minority
You’re viewing 5 of 22 investors. Get the full list »

Nuclera Investments (1)

Nuclera’s most recent deal was a Corporate Asset Purchase with E Ink (Digital Microfluidics Unit) for . The deal was made on 12-May-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
E Ink (Digital Microfluidics Unit) 12-May-2021 Corporate Asset Purchase Buildings and Property
To view Nuclera’s complete investments history, request access »

Ready to get started?

Request a free trial

Nuclera FAQs

  • When was Nuclera founded?

    Nuclera was founded in 2013.

  • Where is Nuclera headquartered?

    Nuclera is headquartered in Cambridge, United Kingdom.

  • What is the size of Nuclera?

    Nuclera has 127 total employees.

  • What industry is Nuclera in?

    Nuclera’s primary industry is Biotechnology.

  • Is Nuclera a private or public company?

    Nuclera is a Private company.

  • What is Nuclera’s current revenue?

    The current revenue for Nuclera is .

  • How much funding has Nuclera raised over time?

    Nuclera has raised $154M.

  • Who are Nuclera’s investors?

    Cambridge Innovation Capital, Elevage Medical Technologies, E-Link Holdings, , and Patient Square Capital are 5 of 22 investors who have invested in Nuclera.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »